Roche struck a $1.7 billion cancer drug pact with Blueprint Medicines, as advances in genetic testing for rare mutations drive lucrative deals for expensive treatments.
Lilly’s targeted RET drug shrinks tumors in lung cancer trial
Acquisitions, Advanced lung cancer, Business, Clinical Trials, European Society for Medical Oncology (ESMO), FDA, Gene Abnormalities, Liver Enzymes, Non-Small Cell Lung Cancer, Papillary Thyroid Cancer, R&D, RET Gene, Tumor Shrinkage, Tumors, World Conference on Lung CancerEli Lilly and Co.’s LOXO-292, an experimental cancer drug the company acquired in January 2019 as part of an $8 billion takeover of Loxo Oncology, shrank tumors in nearly 70 percent of advanced lung cancer patients whose tumors carried specific abnormalities in the RET gene.